

# TYME

to conquer advanced cancers.

## 2021 FACTSHEET

### What Drives Us

Today **15 Million** people are living with cancer

by **2026** **20 Million**



Despite medical innovation, patients with advanced cancer need more and better treatment options

### POSITIVE DATA READOUTS

**ESMO GI Pancreatic:** TYME-88-Panc Study demonstrating encouraging overall survival trends in patients with advanced pancreatic cancer

**ESMO Prostate:** TYME SM-88 Phase II Prostate Cancer Study demonstrating encouraging clinical benefit in patients with recurrent prostate cancer

**AACR 2020:** Presented new preclinical data supporting SM-88 mechanism of action. TYME-18 was also presented. TYME-18 demonstrates anti-cancer effect in new preclinical data.

**TYMEINC.COM**

[twitter.com/tyme\\_inc](https://twitter.com/tyme_inc)

[facebook.com/TYME2ConquerCancers](https://facebook.com/TYME2ConquerCancers)

[linkedin.com/company/tymeinc](https://linkedin.com/company/tymeinc)

revApr2021

## Who We Are

TYME is an **emerging biotechnology** company focused on exploring **novel therapeutic approaches** designed to target cancer's unique metabolism.

TYME is advancing proprietary **Cancer Metabolism-Based Therapies (CMBTs™)** for **metastatic cancers**.

## TYME To Make An Impact

Our unique science gives us the potential to have a significant influence on the current cancer landscape:

- Offering metastatic cancer patients new treatment options to extend and improve quality of life
- Developing a first-in-class oral CMBT, SM-88, showing compelling initial clinical trial results across 15 cancers
- Advancing our pipeline of CMBTs to change the standard of cancer care

## Progress In Our Science Driving Growth

### ADVANCING CLINICAL DEVELOPMENT WITH ADVOCACY PARTNERS

**TYME-88-PANC:** Enrolling Patients in TYME's SM-88 Pivotal Trial in third-line pancreatic cancer. For more details visit <https://tymesm88panctrial.com/>

**PanCAN:** Enrolling patients in Precision Promise<sup>SM</sup> Pivotal Trial with oral SM-88 monotherapy in second-line metastatic pancreatic cancer. Details can be found at <https://clinicaltrials.gov/ct2/show/NCT04229004>

**TYME/JAF HopES Sarcoma Trial:** Enrolling patients in SM-88 Phase II Clinical Trial in Ewing's and high-risk sarcomas through collaboration with JAF and Dr. Chawla. For more details visit <http://tymesm88hopessarcomatrial.com/>

### PUBLICATIONS

SM-88 Shows Promising Preclinical Antitumor Activity Across Several Cancers **OnLive**


Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future **The Lancet Oncology**

A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer **Investigational New Drugs**

### REGULATORY

FDA granted TYME Orphan Drug Designation for SM-88 (racemetyrosine), as a potential treatment for patients with pancreatic cancer

## Investment Rationale



## Our Team

**Steve Hoffman**  
Co-Founder, Chairman,  
and Chief Science Officer


**Richie Cunningham**  
Chief Executive Officer

**Jan M. Van Tornout, MD, MSc**  
Chief Medical Officer

**Jonathan Eckard, Ph.D.**  
Chief Business Officer


**John Rothman, Ph.D.**  
Executive VP of Product Development

## Delivering on Key Milestones Positions TYME for Long-Term Success



## A Look Beyond:

Expanding Innovative Pipeline of Cancer Metabolism-Based Compounds (CMBTs™)



\* Investigator-initiated trial  
GA = gemcitabine/Abraxane®